It would be interesting to further evaluate the clinical value of vascular CXCR4, perhaps by determining both tumor cell and vascular CXCR4 expression (co-localised with CD31 for indication of vasculature) and correlating this with other malignancy processes, such as angiogenesis, metastatic potential, and, at later stages, patient survival. The gene discussed is PECAM1; the disease is neoplasm.